Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theralux ECP in Refractory Chronic GvHD
NCT00248365Phase 2Completed
- Sponsor
- Kiadis Pharma
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of TH9402 in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Kiadis Pharma. Primary endpoints: Signs of toxicity, Chronic GvHD grading and 1 more. Started Nov 2005; status: completed.
02
Drugs
TH9402
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00248365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248365.